Salt Lake City, UTNCT07521046Now EnrollingIRB Ready

Myelofibrosis Clinical Trial in Salt Lake City, UT

Access cutting-edge myelofibrosis treatment through this phase 1 clinical trial at a research site in Salt Lake City. Study-provided care at no cost to qualified participants.

Sponsored by University of Utah

Quick Self-Assessment

See if you qualify for this Salt Lake City location

Preparing your pre-screening questions…

Expert Care in Salt Lake City

Access myelofibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related myelofibrosis treatment provided free

Apply for This Salt Lake City Location

Check if you qualify for this myelofibrosis clinical trial in Salt Lake City, UT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Salt Lake City

    Convenient for UT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Salt Lake City site if eligible
  4. 4Begin participation

About This Myelofibrosis Study in Salt Lake City

The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.

Sponsor: University of Utah

Who Can Participate

Inclusion Criteria

Male or female subject aged ≥ 18 years.
Diagnosed with PMF, post-PV MF, or post-ET MF per WHO 2016 or 2022 criteria, bearing one of these MPN phenotype defining mutations (JAK2, CALR, and MPL), and with a DIPSS score of low, intermediate-1 or intermediate-2.
Subjects must be already on standard of care ruxolitinib per the treating physician for at least 3 months or more, and on a stable dose for at least 6 weeks prior to screening.
Subjects must have spleen volume of \> 450ml by either MRI or CT scan
Subject must have a JAK2, CALR, or MPL allelic burden of ≥20% at screening --Prior treatment for PV or ET with hydroxyurea or ruxolitinib is allowed. If the patient was on pegylated interferon in the past, the progression from PV/ ET to post-PV/ET MF must not have occurred while on pegylated interferon therapy.
ECOG Performance Status ≤ 2.
Adequate organ function as defined as:
Hematologic:
WBC count ≥ 4 x 109/L
Absolute neutrophil count (ANC) ≥1500/mm3
Platelet count ≥ 75,000/mm3
Hemoglobin ≥ 8 g/dL
Hepatic: ---Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN) ---AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN
Estimated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula
Recovery to baseline or ≤ Grade 1 CTCAE v 6.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy per the treating investigator.
Participants must adhere to the following sex and contraceptive/barrier requirements:
If participant is of childbearing potential, they must have a negative pregnancy test
For participants of non-childbearing potential: The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
\< 50 years of age: ---Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and ---Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution --≥ 50 years of age: ---Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or ---Had radiation-induced menopause with last menses \>1 year ago; or ---Had chemotherapy-induced menopause with last menses \>1 year ago ---Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception and lactation requirements as described in Sections 6.4.1 and 6.4.3.
Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria

PV or ET patients who progressed while on pegylated interferon or ropeginterferon therapy.
Receiving other investigational agents.
Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt (Patients with pre-existing depression who are well-controlled and on stable doses of antidepressants are eligible).
Evidence of severe retinopathy or clinically significant eye disease.
History or presence of active serious or untreated autoimmune disease.
History of solid organ transplant.
Liver cirrhosis Child-Pugh score B or C. -≥ 5% blasts in peripheral blood or bone marrow.
Prior systemic anti-cancer therapy or any investigational therapy ≤ 14 days or within five half-lives prior to starting study treatment, whichever is shorter.
Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery.
The diagnosis of another malignancy which, in the investigator's opinion, is likely to significantly impact study participation.
Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:
Cardiovascular disorders:
Uncontrolled hypertension, in the opinion of the investigator
Congestive heart failure New York Heart Association Class II or greater, unstable angina pectoris, serious cardiac arrhythmias.
Stroke or myocardial infarction within the past 3 months
Significant coronary stenosis, in the opinion of the investigator
QTc prolongation defined as a QTcF \> 500 ms.
Known congenital long QT.
Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, \[subjects may not receive the drug through a feeding tube\], social/ psychological issues, etc.)
Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial. -Active infection requiring systemic therapy, including, but not limited to: tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C. Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study.
Known prior severe hypersensitivity to investigational product (IP) or any component in its formulations (NCI CTCAE v 6.0 Grade ≥ 3).
Subjects taking prohibited medications as described in Section 7.8. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Salt Lake City?

Yes, this clinical trial (NCT07521046) has an active research site in Salt Lake City, UT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Myelofibrosis Treatment Options in Salt Lake City, UT

If you're searching for myelofibrosis treatment options in Salt Lake City, UT, this clinical trial (NCT07521046) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Salt Lake City research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all myelofibrosis clinical trials near you to find additional studies recruiting in your area.

More Myeloproliferative Neoplasms Trials in Salt Lake City, UT

See all myeloproliferative neoplasms clinical trials recruiting in Salt Lake City — not just this study.

Browse Myeloproliferative Neoplasms Trials in Salt Lake City →

Browse More Trials by Condition

Myeloproliferative Neoplasms TrialsFibromyalgia TrialsMyelofibrosis TrialsAll Conditions →

Ready to Join in Salt Lake City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Salt Lake City, UT